Impact of Bacillus amyloliquefaciens CECT 5940 supplementation on gut health and growth performance of broilers under commercial conditions
Antimicrobial growth promoters (AGPs) have been used in broiler feeding for many decades to improve gut health and performance. However, prolonged use of AGP has been associated with the potential problem of antimicrobial resistance in birds and also in humans. European commission banned the usage of antibiotics in animal feeding since 2006. There have been ongoing pressures from consumers on elimination or reduction of AGP in poultry diets. Removal of AGP in broiler diets led to reduced performance, and increased gastrointestinal (GIT) diseases (Huyghebaert et al., 2011). One of the major GIT disturbances is dysbacteriosis, which is defined as an imbalance in the gut microbiota as a consequence of an intestinal disruption. Dysbacteriosis results in poor nutrient absorption in the gut leading to poor growth. If dysbacteriosis is severe, it could result in wet litter in broilers, consequently leading to high mortality.
To minimize the negative consequences of AGP-free diets on broiler performance, several nutritional strategies have been implemented globally. Among the feed additives, probiotics appears to be a promising alternative to AGPs because they have specific mechanism of actions that could improve and maintain a stable gut microbiome. Furthermore, it reduces the GIT diseases and consequently results in improved performance (Ducatelle et al., 2015).
A Bacillus amyloliquefaciens CECT 5940 strain is a patented probiotic produced by Evonik (Ecobiol®) and this strain was selected from hundreds of naturally occurring Bacillus spp. isolates based on strict screening for heat stability, viability in the intestinal tract conditions of broilers and the potential for secondary metabolite expression. A trial was conducted to evaluate the effects of B. amyloliquefaciens probiotic in water soluble form on broiler performance and intestinal health under commercial conditions.
Materials and Methods
A total of 242,880, day-old mixed-sex broilers (Cobb 500) were randomly distributed to 2 treatments [a control (CONT) and a probiotic (PRO)] in 12 different building units (6 building replicates/treatment; 20,240 birds /building). All the birds were fed commercial broiler diets without AGP and followed routine vaccination and anti-coccidial program. In CON group, Tylosin and Amoxicillin were added in drinking water during d 2 to 6 and d 9 to 11 as a prophylactic medication, respectively. In PRO group, birds were fed antibiotic-free water and provided probiotic (ECOBIOL® soluble plus) in drinking water at the rate of 50 g per 1000 L water daily. Final BW and feed consumption were measured to calculate FCR. Data were subjected to ANOVA and analyzed as a simple T-test using SAS 9.4. Significance was reported for P < 0.05. Each building was considered as an experimental unit.
Data on broiler performance are presented in Table 1. The livability percent was similar (P > 0.05) among the treatments. The final BW in PRO was significantly higher (P < 0.05) than CONT (2.84 kg vs. 2.76 kg). The PRO birds had improved FCR compared with CONT (1.733 vs. 1.805) which in agreement with the previous studies (Facts and Figures 15160, 15168). European performance index in PRO group was significantly higher (P < 0.05) than CONT group (353.8 vs. 315.2). Intestinal lesions and also sloughing with mucous exudate were predominantly found in broilers fed CON, whereas, intestinal lesions were relatively lower for broilers fed PRO (Fig 1).
Bacillus amyloliquefaciens CECT 5940 increased growth performance by improving intestinal health in broilers under commercial feeding conditions.
Data indicated that supplementation of Bacillus amyloliquefaciens CECT 5940 can replace water soluble antibiotics program as prevention/prophylactic medication.
Overall, probiotic Bacillus amyloliquefaciens CECT 5940 could be used for improving gut health and growth performance in AGP-free broiler feeding under commercial conditions.
Fig 1. Illustrated pics showing intestinal lesions
For more of the article, please click here.
Article made possible through the contribution of Chavalit Piriyabenjawat, Balachandar Jayaraman, Girish Channarayapatna and Evonik (SEA) Pte. Ltd. Singapore